Abic Marketing Ltd, Israel

NSAID. Diclofenac Sodium 50 mg.
SUPPS: 10. 2 supps. at night.
Rheumat. arthr., osteoarthr., low back pain,
other acute musculosk. disord. such as
periarthr., tendin., tenosynov., bursitis,
sprains, strains, dislocation, ankyl.
spondylitis, acute gout. Control of pain/
inflamm. in orthopedic, dental, and other
minor surgery.
S.R. TABS: 20. 1 tab. dly.
Rheum. arthrit., other rheum. conds.
C/I: Hypersens. to the product. Active
gastr./ intest. ulcer, bleeding or perfor.
Active/ history of recur. peptic ulcer/
haemorrhage (>=2 distinct epis. of
proven ulcer./ bleeding). History of GI
bleeding/perfor., relating to prev. NSAID
tmt. Last trimester of pregn. Sev. hepatic
and renal failure. Establ. CHF (NYHA class
II-IV), isch. heart dis., periph. arter. dis.,
cerebrovasc. dis. Pts. in whom aspirin or
other NSAIDs have induc. sympt. of
asthma, acute rhinitis precipit. by
ibuprofen, urticaria, nasal polyps,
angioedema, bronchospasm, other
sympt. of allergic react. (anaphyl. react.
have occur. in such pts). Pts with sev.
heart failure. Tmt of peri-operative pain
in CABG surg.

Opioid. Fentanyl (as citrate) 200, 400, 600, 800, 1200, 1600 mcg/dose.
COMPRESSED TAB. ON HANDLE
(lozenge): 30. Initial: 200 μg. To supply
only 6 x 200 μg and to use all units bef. incr. to higher dose. See lit. Unit to be
sucked, not chewed over 15 mins.
Discont: Grad. downward titrat.
Manage. breakthrough cancer pain in pts
16 and older with maligns. who are
already receiv. and tolerant to opioid ther.
for persist. cancer pain.
C/I: Post-op. pain, opioid non-tol.,
hypersens./intol. to fentanyl, anaphylax.
See lit.

Calcitonin gene-related peptide (CGRP) antagonists.. Fremanezumab 225 mg.
PRE-FILL. SYR. (Sol.for  S.C. inj.):1, 3×1.5ml.
PRE-FILL PEN (Sol.for  S.C. inj.): 1, 3×1.5 ml. Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with fremanezumab.
Two dosing options are avail.:
225 mg once mnthly 675 mg every 3 mnths. (quarter. dosing)
When switch. dosing regimens, the 1^st  dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiating treatment with fremanezumab, concom. migraine prevent. tmt. may be contin. if consid. necessary by the prescriber .
The tmt. benefit should be assessed within 3 mnths. after initiat. of tmt. Any further decision to cont. tmt. should be taken on an individ. pt. basis. Evaluat. of the need to cont. tmt. is recomm. regularly thereafter.
Missed dose - dosing should resume as soon as possible on the indicat. dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicated for prophylax. of migraine in adults who have at least 4 migraine days per
month.
C/I: Hypersens. react. such as rash, pruritus, urticaria and swell. have been reported uncommon. with fremanezumab. Most react. were reported from within hrs. to one month after admin. and were mild – moder., but some led to discount. or required corticosteroid tmt. If a hypersens. reaction occurs, discount. of fremanezumab admin. should be consid.and appropriate ther. should be initiated.

 

α1 Blocker. Alfuzosin HCl 10 mg.
E.R. TABS: 30. 10 mg dly, immed. aft.
even. meal. Swallow whole with fluid.
Not to be crushed, chew. or divid.
Start ther. on day of insert. of urethral
cath. Tmt. 3-4 days, i.e. 2-3 days
during catheterizat. and 1 day follow.
removal.
Tmt. funct. sympts. BPH, espec. if surg.
delayed. Adjuv. tmt. to cathet. in acute
urinary retent. rel. to BPH.
C/I: Known hypersens., postural
hypotens., liver fail., severe kidney fail.,
combinat. with other alpha 1 blockers,
child.